These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15383670)

  • 21. Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently.
    Nefkens I; Negorev DG; Ishov AM; Michaelson JS; Yeh ET; Tanguay RM; Müller WE; Maul GG
    J Cell Sci; 2003 Feb; 116(Pt 3):513-24. PubMed ID: 12508112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions.
    Wu WS; Xu ZX; Ran R; Meng F; Chang KS
    Oncogene; 2002 May; 21(24):3925-33. PubMed ID: 12032831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2.
    Florin L; Becker KA; Lambert C; Nowak T; Sapp C; Strand D; Streeck RE; Sapp M
    J Virol; 2006 Jul; 80(13):6691-6. PubMed ID: 16775357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of endogenous human promyelocytic leukemia isoforms.
    Condemine W; Takahashi Y; Zhu J; Puvion-Dutilleul F; Guegan S; Janin A; de Thé H
    Cancer Res; 2006 Jun; 66(12):6192-8. PubMed ID: 16778193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding.
    Fay A; Yutzy WH; Roden RB; Moroianu J
    J Virol; 2004 Dec; 78(24):13447-54. PubMed ID: 15564455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
    Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assembly of Epstein-Barr Virus Capsid in Promyelocytic Leukemia Nuclear Bodies.
    Wang WH; Kuo CW; Chang LK; Hung CC; Chang TH; Liu ST
    J Virol; 2015 Sep; 89(17):8922-31. PubMed ID: 26085145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient mutations alter ATRX targeting to PML nuclear bodies.
    Bérubé NG; Healy J; Medina CF; Wu S; Hodgson T; Jagla M; Picketts DJ
    Eur J Hum Genet; 2008 Feb; 16(2):192-201. PubMed ID: 17957225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus.
    Nakahara T; Lambert PF
    Virology; 2007 Sep; 366(2):316-29. PubMed ID: 17543368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear dots: actors on many stages.
    Sternsdorf T; Grötzinger T; Jensen K; Will H
    Immunobiology; 1997 Dec; 198(1-3):307-31. PubMed ID: 9442402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.
    Everett RD; Meredith M; Orr A; Cross A; Kathoria M; Parkinson J
    EMBO J; 1997 Feb; 16(3):566-77. PubMed ID: 9034339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
    Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
    Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of the papillomavirus transcription/replication factor, E2, and the viral capsid protein, L2.
    Heino P; Zhou J; Lambert PF
    Virology; 2000 Oct; 276(2):304-14. PubMed ID: 11040122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
    Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
    J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1.
    Maul GG; Ishov AM; Everett RD
    Virology; 1996 Mar; 217(1):67-75. PubMed ID: 8599237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A role for PML and the nuclear body in genomic stability.
    Zhong S; Hu P; Ye TZ; Stan R; Ellis NA; Pandolfi PP
    Oncogene; 1999 Dec; 18(56):7941-7. PubMed ID: 10637504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus.
    Reichelt M; Wang L; Sommer M; Perrino J; Nour AM; Sen N; Baiker A; Zerboni L; Arvin AM
    PLoS Pathog; 2011 Feb; 7(2):e1001266. PubMed ID: 21304940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
    Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
    Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
    Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein.
    Kieback E; Müller M
    Virology; 2006 Feb; 345(1):199-208. PubMed ID: 16257028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.